• Cubist Pharmaceuticals Inc., of Lexington, Mass., reported top-line results from its pivotal Phase III study of antibiotic candidate ceftolozane/tazobactam in complicated urinary tract infections, showing that the study met its primary endpoint of statistical noninferiority compared to levofloxacin (10 percent noninferiority margin).